Kevzara (sarilumab) vs Yuflyma (adalimumab-aaty)

Kevzara (sarilumab) and Yuflyma (adalimumab-aaty) are both used to treat inflammatory conditions such as rheumatoid arthritis, but they work in different ways. Kevzara is an interleukin-6 (IL-6) receptor antagonist, which means it helps reduce inflammation by blocking the activity of IL-6, a protein involved in the immune response. In contrast, Yuflyma, a biosimilar to Humira (adalimumab), is a tumor necrosis factor (TNF) blocker that helps reduce inflammation by inhibiting the action of TNF, another protein that plays a role in inflammatory processes. When deciding which medication is right for an individual, it is important to consider factors such as the specific condition being treated, the patient's medical history, potential side effects, and how the medicine is administered, as Kevzara is typically given as an injection under the skin every two weeks, while Yuflyma is also administered as a subcutaneous injection but may have different dosing schedules. It is essential to consult with a healthcare provider to determine the most appropriate treatment based on the individual's unique circumstances.

Difference between Kevzara and Yuflyma

Metric	Kevzara (sarilumab)	Yuflyma (adalimumab-aaty)
Generic name	Sarilumab	Adalimumab-aaty
Indications	Rheumatoid arthritis	Multiple inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis
Mechanism of action	Interleukin-6 receptor antagonist	Tumor necrosis factor (TNF) blocker
Brand names	Kevzara	Yuflyma
Administrative route	Subcutaneous injection	Subcutaneous injection
Side effects	Upper respiratory infections, elevated liver enzymes, injection site reactions, neutropenia	Infections, injection site reactions, headache, rash, nausea
Contraindications	Hypersensitivity to sarilumab or any of its excipients, active infection	Hypersensitivity to adalimumab or any of its excipients, active tuberculosis or other severe infections
Drug class	Immunosuppressant, Disease-modifying antirheumatic drug (DMARD)	Immunosuppressant, Disease-modifying antirheumatic drug (DMARD)
Manufacturer	Sanofi and Regeneron Pharmaceuticals	Celltrion Healthcare

Efficacy

Kevzara (Sarilumab) for Rheumatoid Arthritis

Kevzara (sarilumab) is an interleukin-6 (IL-6) receptor antagonist approved by the FDA for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). The efficacy of Kevzara in treating RA was demonstrated in several pivotal clinical trials, including the MOBILITY and TARGET studies. These trials showed that Kevzara, when used alone or in combination with conventional DMARDs, significantly reduced signs and symptoms of RA, improved physical function, and inhibited the progression of joint damage compared to placebo.

In the MOBILITY trial, patients treated with Kevzara plus methotrexate achieved a greater reduction in the American College of Rheumatology criteria of 20% improvement (ACR20) compared to those who received methotrexate alone. Additionally, Kevzara was shown to improve outcomes as early as two weeks after starting treatment, with continued improvement over time. The TARGET study further confirmed the efficacy of Kevzara in a population of patients who were intolerant to or had an inadequate response to tumor necrosis factor (TNF) inhibitors.

Yuflyma (Adalimumab-aaty) for Rheumatoid Arthritis

Yuflyma (adalimumab-aaty) is a biosimilar to the reference product Humira (adalimumab) and is approved for the same indications, including the treatment of rheumatoid arthritis. As a biosimilar, Yuflyma has demonstrated no clinically meaningful differences in terms of safety, purity, and potency when compared to Humira. In clinical studies, Yuflyma effectively reduced the signs and symptoms of RA, induced major clinical response, inhibited the progression of structural damage, and improved physical function in adult patients with moderately to severely active disease.

The approval of Yuflyma was based on a comprehensive data package that included analytical, preclinical, and clinical research, confirming its biosimilarity to Humira. Clinical trials specifically assessing the efficacy of Yuflyma in RA patients have shown that the biosimilar achieves similar ACR20, ACR50, and ACR70 response rates compared to the reference product. This indicates that patients with RA can expect comparable therapeutic results with Yuflyma as with the original adalimumab product.

Regulatory Agency Approvals

Kevzara

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia

Yuflyma

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Kevzara or Yuflyma today

If Kevzara or Yuflyma are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Kevzara

Buy Yuflyma

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: